This month we focussed on the way technology is converging with medicines development and healthcare, and how IMI-funded research is putting Europe at the front lines of this evolution. Innovation in digital technology coupled with the push for personalised medicine have accelerated the changes we now see in the way clinical trials are run, big data is exploited, and the way promising molecules are singled out for development.
But this is new territory for everyone. IMI can facilitate the discussions that need to take place between technology companies and regulators, pharma companies and scientists, as well as those who are going make decisions about reimbursement. We can provide a transparent, neutral and, importantly, pre-competitive setting - one of the ideas that is driving the creation of IMI’s successor, one of Europe’s new health partnerships. The technology will move very quickly, so we should, too.